Occupancy
65%
flat YoY
Group occupancy remained at 65% despite ALOS reduction and bed recalibration; metro hospitals above 70%.
APOLLOHOSP
Healthcare
14 May 2024
Apollohosp Ltd — Q4 FY24
Apollo Hospitals reported a strong Q4 FY24 with consolidated revenue of INR 4,944 crore (up 15% YoY) and EBITDA of INR 641 crore (up 31% YoY).
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Apollo Hospitals reported a strong Q4 FY24 with consolidated revenue of INR 4,944 crore (up 15% YoY) and EBITDA of INR 641 crore (up 31% YoY). Healthcare services revenue grew 17% YoY, driven by 6.1% IP volume growth and 12% ARPOB increase to INR 59,523. Occupancy stood at 65%, with metro hospitals above 70%. The company added 150 new doctors, which temporarily impacted healthcare services margins (23.1%), but management expects a 150 bps margin expansion in FY25. Apollo 24/7 achieved positive EBITDA of INR 12 crore, with a target to breakeven in 6-8 quarters. Pharmacy distribution growth was impacted by inventory rationalization. Guidance includes 15%+ healthcare services growth, 50% GMV growth for Apollo 24/7, and 500-550 new pharmacy stores. Risk: New hospital ramp-up and doctor hiring may delay margin recovery.
अपोलो हॉस्पिटल्स ने चौथी तिमाही में अच्छा प्रदर्शन किया। कुल कमाई 4,944 करोड़ रुपये रही, जो पिछले साल से 15% ज्यादा है। कमाई पर मुनाफा (EBITDA) 641 करोड़ रुपये रहा, जो 31% बढ़ा। अस्पताल सेवाओं की कमाई 17% बढ़ी, क्योंकि मरीजों की संख्या 6.1% और प्रति मरीज खर्च 12% बढ़कर 59,523 रुपये हो गया। 65% बिस्तर भरे रहे, बड़े शहरों में 70% से ज्यादा। 150 नए डॉक्टर जुड़ने से मुनाफा मार्जिन 23.1% रहा, लेकिन अगले साल इसमें 1.5% सुधार की उम्मीद है। अपोलो 24/7 ने 12 करोड़ रुपये का मुनाफा कमाया और 6-8 तिमाहियों में बराबर होने का लक्ष्य है। फार्मेसी की बिक्री स्टॉक कम करने से प्रभावित हुई। आगे अस्पताल सेवाओं में 15% से ज्यादा, अपोलो 24/7 में 50% और 500-550 नई फार्मेसियों की योजना है। जोखिम: नए अस्पताल और डॉक्टरों की भर्ती से मुनाफा सुधार में देरी हो सकती है।
Key Numbers
ARPOB
INR 59,523
+12% YoY
Average revenue per occupied bed increased 12% year-on-year, driven by better case mix and payer mix.
Apollo 24/7 GMV
INR 681 crore
+35% YoY
Digital platform GMV grew 35% YoY; 2 million new users added in Q4.
New Pharmacy Stores Added (FY24)
489
-56% YoY
Net addition of 489 pharmacies in FY24 vs 1,100 in FY23, due to inventory rationalization.
What Changed vs Last Quarter
NEW
Healthcare services EBITDA margin expansion of 150 bps in FY25
Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.
NEW
Add 500-550 new pharmacy stores in FY25
Offline pharmacy network expansion to continue at similar pace as FY24.
UPDATED
Healthcare services revenue growth >15% in FY25
Driven by volume growth, network expansion, and better asset utilization.
UPDATED
Apollo 24/7 breakeven in 6-8 quarters
Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.
DROPPED
200 bps margin improvement in healthcare services over next few quarters
Internal target to increase EBITDA margins by 200 basis points through volume growth, clinical program expansion, and cost rationalization.
DROPPED
2,000 beds over four years at INR 3,000 crore capex
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
NEW RISK
New hospital ramp-up may delay margin recovery
Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.
NEW RISK
Doctor hiring costs may not yield immediate volume benefits
150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.
NEW RISK
Inventory rationalization impact on pharmacy distribution
Lower inventory buildup reduced pharmacy distribution sales by ~INR 150 crore in Q4; growth recovery depends on store-level execution.
NEW RISK
Competitive pressure in Nashik market
Nashik hospital remains a drag on western region occupancy due to multiple competitors and low-paying patient mix.
RISK GONE
Margin pressure from new bed additions
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
RISK GONE
Seasonality and one-off events impacting growth
Q3 saw lower elective surgeries due to holidays and Chennai cyclone, affecting revenue mix and margins. Similar events could recur.
RISK GONE
Slowdown in 24/7 daily active users
Despite adding 2 million new users, daily active users declined sequentially, raising concerns about user engagement and monetization.
RISK GONE
Regulatory risk from kidney racket allegations
Allegations of involvement in a kidney racket could impact reputation, though management states no negative findings have been made.
🤫 Topics management stopped discussing
Mentioned in Q2 FY24, Q3 FY24
Expansion plan includes new hospitals in Pune, Hyderabad, Kolkata, and brownfield in Bangalore, with first beds operational in FY25.
Mentioned in Q1 FY24, Q2 FY24
Pharmacy business is on track to achieve INR 10,000 crore in revenue for FY24 with EBITDA margin of 6% or higher.
Mentioned in Q1 FY24, Q3 FY24
New hospitals in Pune, Hyderabad, and Kolkata may initially drag margins due to ramp-up costs, though management expects minimal impact.
Management Guidance
Healthcare services revenue growth >15% in FY25
Driven by volume growth, network expansion, and better asset utilization.
Management guidance revenueHealthcare services EBITDA margin expansion of 150 bps in FY25
Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth.
Management guidance marginsApollo 24/7 breakeven in 6-8 quarters
Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%.
Management guidance growthAdd 500-550 new pharmacy stores in FY25
Offline pharmacy network expansion to continue at similar pace as FY24.
Management guidance expansionKey Risks
New hospital ramp-up may delay margin recovery
Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.
medium · management_commentaryDoctor hiring costs may not yield immediate volume benefits
150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.
medium · analyst_questionInventory rationalization impact on pharmacy distribution
Lower inventory buildup reduced pharmacy distribution sales by ~INR 150 crore in Q4; growth recovery depends on store-level execution.
low · data_observationCompetitive pressure in Nashik market
Nashik hospital remains a drag on western region occupancy due to multiple competitors and low-paying patient mix.
low · management_commentaryNotable Quotes
We are looking at a growth of beyond 15%. This growth will be driven by volume.
Our target is to get to 25%. That's what we have as internal targets.
The Supreme Court said that hospital rates are a function of market rates... it was a very good outcome for the private sector.
Frequently Asked Questions
What was Apollohosp's revenue in Q4 FY24?
Apollohosp reported revenue of ₹4,944 Cr in Q4 FY24, representing a +15% change compared to the same quarter last year.
What guidance did Apollohosp management give for FY25?
Healthcare services revenue growth >15% in FY25: Driven by volume growth, network expansion, and better asset utilization. Healthcare services EBITDA margin expansion of 150 bps in FY25: Targeting 25% margin by end of FY25 through cost optimization and surgical volume growth. Apollo 24/7 breakeven in 6-8 quarters: Targeting GMV of INR 1,700 crore per quarter and take rate improvement from 4% to 8%. Add 500-550 new pharmacy stores in FY25: Offline pharmacy network expansion to continue at similar pace as FY24.
What are the key risks for Apollohosp in FY25?
Key risks include New hospital ramp-up may delay margin recovery — Four new hospitals with 1,500 beds to be operationalized by calendar 2025-26; initial costs could pressure margins.; Doctor hiring costs may not yield immediate volume benefits — 150 new doctors hired in FY24; full revenue contribution expected only by Q2 FY25, posing near-term margin risk.; Inventory rationalization impact on pharmacy distribution — Lower inventory buildup reduced pharmacy distribution sales by ~INR 150 crore in Q4; growth recovery depends on store-level execution.; Competitive pressure in Nashik market — Nashik hospital remains a drag on western region occupancy due to multiple competitors and low-paying patient mix..
Did Apollohosp meet its previous quarter's guidance?
Of 1 tracked promise, management 0 met, 0 close, 1 missed.
Where can I read the full Apollohosp Q4 FY24 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.